Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085421 | 0.85 | IDO1 (0.67) | SMN1; SMN2KMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL7085424 | 0.85 | IDO1 (0.67) | SMN1; SMN2KMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL7086561 | 0.85 | IDO1 (0.67) | SMN1; SMN2KMT2AMEN1ALDH1A1RAB9A | |
| SCHEMBL7541492 | 0.85 | TNKS2 (0.51) | PARP1TSHRSMN1; SMN2PKMPARP2 | |
| SCHEMBL30176871 | 0.84 | TNKS2 (0.57) | PARP1TSHRSMN1; SMN2PARP2TNKS2 | |
| SCHEMBL25364009 | 0.83 | TNKS2 (0.56) | PARP1SMN1; SMN2PARP2TNKS2PDE10A | |
| Hydrochloric Acid SCHEMBL6795779 | 0.82 | TNKS2 (0.55) | PARP1PARP2TNKS2PDE10AKMT2A | |
| SCHEMBL38658339 | 0.80 | KMT2A (0.58) | PARP1SMN1; SMN2PARP2TNKS2PDE10A | |
| SCHEMBL7677632 | 0.80 | PARP2 (0.47) | PARP1TSHRSMN1; SMN2PKMPARP2 | |
| SCHEMBL7541212 | 0.80 | PARP2 (0.47) | PARP1TSHRSMN1; SMN2PKMPARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380205-B1 | QUINAZOLINE THROUGH A C1-C4ALKYL, C1- C4ALKENYL, C1-C4ALKYNYL, C1-C4ALKOXY, AMINO, AMINOC1-C4ALKYL, HYDROXYC1-C4ALKYL, CARBONYL, CYCLOC3-C6ALKYL OR AMINOCARBONYL CHAIN, USEFUL FOR TREATMENT OF THE PAIN | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | PARP1 1856/4885TSHR 4548/4885SMN1; SMN2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.